Zejula (Niraparib)

Zejula (niraparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor used:

• for the maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) who are in a complete or partial response to first-line platinum-based chemotherapy. 
• for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian cancer, fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) who are in a complete or partial response to platinum-based chemotherapy.

Recommended Dosage: The recommended dosage of Zejula is taken at approximately the same time each day. Continue treatment until there is evidence of disease progression or unacceptable toxicity. Swallow each tablet whole and do not chew, crush, or split before swallowing. Tablets may be taken with or without food. Bedtime administration may be a potential method to manage nausea. 

First-Line Maintenance Treatment of Advanced Ovarian Cancer:

• The recommended dosage for patients weighing <77 kg (<170 lbs) OR with a platelet count of <150,000/mcL is 200 mg taken orally once daily.
• The recommended dosage for patients weighing ≥77 kg (≥170 lbs) AND who have a platelet count ≥150,000/mcL is 300 mg taken orally once daily.
• For the maintenance treatment of advanced ovarian cancer, start treatment no later than 12 weeks after their most recent platinum-containing regimen.

Maintenance Treatment of Recurrent Germline BRCA-mutated Ovarian Cancer:

• The recommended dosage is 300 mg taken orally once daily. 
• For the maintenance treatment of recurrent ovarian cancer, start treatment no later than 8 weeks after their most recent platinum-containing regimen.
• In the case of a missed dose, instruct patients to take their very next dose at its regularly scheduled time. If a patient vomits or misses a dose, an additional dose of Niraparib needs to be taken.

• Treatment with Niraparib 100 mg/200 mg/300 mg tablets may increase the risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Monitor blood counts regularly during treatment. Seek medical advice in case unusual signs such as pale skin, fatigue, or easy bruising occur.
• This therapeutic drug can cause bone marrow suppression. This may lead to low blood cell counts. Monitor for signs and symptoms like fatigue, unusual bleeding, or infections. Regular blood tests are important to check for issues related to bone marrow.
• This medicine may cause high blood pressure and some other cardiovascular complications. Monitor blood pressure regularly. In case you experience shortness of breath, chest pain, or swelling, contact your healthcare provider (HCP) immediately.
• Posterior Reversible Encephalopathy Syndrome (PRES) can cause headaches, vision problems, confusion, and seizures. In case you experience any of these signs and symptoms, seek prompt medical help. Early detection and stopping this treatment can help prevent permanent damage.
• This therapeutic drug may cause harm to an unborn baby. Do not use it during pregnancy unless the potential benefit outweighs the risks. Women of reproductive potential should use an effective contraception method during treatment and for some time after stopping treatment with Niraparib.
• Zejula 100 mg/200 mg/300 mg tablets may pass into human breast milk and cause harm to a nursing infant. It is recommended to avoid breastfeeding while on this treatment. Consult your healthcare provider (HCP) before breastfeeding.
• Females as well as males should use an effective and appropriate contraception method while taking on treatment and for a period after discontinuing the treatment. Discuss fertility preservation options with your healthcare provider (HCP) before initiating treatment.

What documents are required to import ZEJULA to India?

ZEJULA (niraparib) tablets can be imported by patients or government hospitals in the patients’ name only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is ZEJULA available in India?

ZEJULA (niraparib tablet) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Zejula in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

ZEJULA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ZEJULA (a prescription medicine) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Zejula 100 mg/200 mg/300 mg tablet price in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source ZEJULA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Zejula®?

Niraparib is the Generic Name for the trade name drug Zejula®.

What is the Manufacturer’s Name of Zejula®?

Zejula® is manufactured by GlaxoSmithKline.

Is Zejula® approved by the FDA?

Yes, Zejula® is approved by the FDA. Date of first approval: March 27, 2017.

What is the dosage and form of Zejula® supplied?

Zejula® is supplied in Tablets: 100 mg, 200 mg, 300 mg for oral administration. It can only be obtained with a prescription.

What are the most common side effects of Zejula®? 

The most common side effects of Zejula® are anemia, nausea, thrombocytopenia, fatigue, constipation, vomiting, musculoskeletal pain, abdominal pain, dyspnea, cough, neutropenia, rash, decreased appetite, urinary tract infection, leukopenia, insomnia, hypertension, headache, diarrhea, dizziness, acute kidney injury, and hypomagnesemia

How much does the Zejula® 100 mg/200 mg/300 mg Tablet cost in India?

Prices of Zejula may fluctuate over time due to market dynamics and regulatory changes. To get the most accurate and latest details on Zejula 100 mg/200 mg/300 mg tablet cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Zejula® 100 mg/200 mg/300 mg Tablets be available in SAARC countries? 

Apart from Gulf countries, Zejula® 100 mg/200 mg/300 mg can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Zejula® tablets in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Zejula® 100 mg/200 mg/300 mg Tablets online in India?

Yes, one can buy Zejula 100 mg/200 mg/300 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Zejula® oral tablets through legal channels. 

What are the storage conditions of Zejula® 100 mg/200 mg/300 mg tablets?

Store and dispense this medicine in the original bottle. Store at 20 to 25°C (68 to 77°F); excursions are permitted between 15 to 30°C (59 to 86°F).